Stock NRXS NEURAXIS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

NeurAxis, Inc. Stock

Equities

NRXS

US64134X2018

Medical Equipment, Supplies & Distribution

Delayed Nyse
Other stock markets
 09:40:51 2024-04-29 am EDT 		5-day change 1st Jan Change
3.1 USD -4.62% Intraday chart for NeurAxis, Inc. -2.36% +16.10%
Apr. 16 NeurAxis, Inc. Terminates Dan Clarence as Chief Operating Officer CI
Apr. 09 NeurAxis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials (USD)

Sales 2024 * 11.65M Sales 2025 * - Capitalization 21.43M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 1.84 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 19
Yield 2024 *
-
Yield 2025 *
-
Free-Float 61.92%
More Fundamentals * Assessed data

Chart NeurAxis, Inc.

Dynamic Chart

Latest news about NeurAxis, Inc.

NeurAxis, Inc. Terminates Dan Clarence as Chief Operating Officer CI
NeurAxis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
NeurAxis, Inc. Provides Revenue Guidance in Late 2024 and into 2025 CI
NeurAxis, Inc. Announces IB-Stim Results from A Large, Pediatric, Multi-Center Registry CI
Neuraxis, Inc. Appoints Kristin Ferge to the Board CI
Top Premarket Decliners MT
Certain Common Stock of NeurAxis, Inc. are subject to a Lock-Up Agreement Ending on 5-FEB-2024. CI
Certain Preferred Stock of NeurAxis, Inc. are subject to a Lock-Up Agreement Ending on 5-FEB-2024. CI
Certain Options of NeurAxis, Inc. are subject to a Lock-Up Agreement Ending on 5-FEB-2024. CI
Certain Warrants of NeurAxis, Inc. are subject to a Lock-Up Agreement Ending on 5-FEB-2024. CI
NeurAxis Names Timothy Henrichs Finance Chief MT
NeurAxis, Inc. Announces Resignation of Timothy Henrichs as Independent Director CI
NeurAxis, Inc. Appoints Timothy Henrichs as Chief Financial Officer, Effective February 5, 2024 CI
NeurAxis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
NeurAxis, Inc. announced that it expects to receive $3 million in funding from Flagstaff International, Inc CI
More news

Press releases NeurAxis, Inc.

NeurAxis Announces New Medical Policy Coverage in North Dakota GL
NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results GL
NeurAxis to Host Fourth Quarter and Full Year 2023 Results and Business Update Call on Tuesday, April 9, 2024 GL
NeurAxis Announces IB-Stim Results from a Large, Pediatric, Multi-Center Registry GL
NeurAxis Announces Highmark BCBS Policy Coverage GL
More press releases

Quotes and Performance

1 day-4.62%
1 week-2.36%
Current month-0.64%
1 month-4.62%
3 months+33.62%
6 months+45.54%
Current year+16.10%
More quotes

Highs and lows

1 week
2.60
Extreme 2.6
3.25
1 month
2.60
Extreme 2.6
3.44
Current year
2.00
Extreme 2.0001
3.89
1 year
1.80
Extreme 1.8
6.93
3 years
1.80
Extreme 1.8
6.93
5 years
1.80
Extreme 1.8
6.93
10 years
1.80
Extreme 1.8
6.93
More quotes

Managers and Directors - NeurAxis, Inc.

Managers TitleAgeSince
Gary Peterson FOU
 Founder - 10-12-31
Brian Carrico CEO
 Chief Executive Officer 42 11-12-31
Timothy Henrichs DFI
 Director of Finance/CFO 51 Feb. 04
Members of the board TitleAgeSince
Brian Carrico CEO
 Chief Executive Officer 42 11-12-31
Christopher Robin Brown FOU
 Founder 70 10-12-31
Tom Carrico CMP
 Compliance Officer 67 12-01-31
More insiders

Quotes

Date Price Change Volume
24-04-29 3.1 -4.62% 120
24-04-26 3.25 +8.33% 4,706
24-04-25 3 0.00% 6,915
24-04-24 3 +6.38% 16,270
24-04-23 2.82 -11.18% 17,985

Delayed Quote Nyse, April 29, 2024 at 09:40 am EDT

More quotes

Company Profile

Neuraxis, Inc. is a growth-stage company that is primarily focused on developing neuromodulation therapies to address chronic and debilitating conditions in children. The Company is involved in advancing the science with its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The Company’s pipeline B-Stim device is used for the indication of functional abdominal pain associated with irritable bowel syndrome (IBS) and functional nausea in children. The IB-Stim is a PENFS system intended to be used in patients 11-18 years of age with functional abdominal pain associated with IBS. The United States Food and Drug Administration (FDA) pipeline has indications, including chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome.
Sector
Medical Equipment, Supplies & Distribution
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.25 USD
Average target price
7.5 USD
Spread / Average Target
+130.77%
Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Medical Equipment

1st Jan change Capi.
NEURAXIS, INC. Stock NeurAxis, Inc.
+16.10% 21.43M
SHOCKWAVE MEDICAL, INC. Stock Shockwave Medical, Inc.
+72.96% 12.38B
PENUMBRA, INC. Stock Penumbra, Inc.
-18.57% 7.92B
MASIMO CORPORATION Stock Masimo Corporation
+16.18% 7.2B
GETINGE AB Stock Getinge AB
+6.78% 5.84B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD. Stock Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
+7.49% 5.07B
APT MEDICAL INC. Stock APT Medical Inc.
+23.97% 4.53B
ASAHI INTECC CO., LTD. Stock Asahi Intecc Co., Ltd.
-21.67% 3.88B
INARI MEDICAL, INC. Stock Inari Medical, Inc.
-40.30% 2.23B
SKAN GROUP AG Stock SKAN Group AG
+1.24% 2.02B
Medical Equipment
  1. Stock Market
  2. Equities
  3. NRXS Stock